血清视黄醇结合蛋白4可作为老年人肌少症的潜在生物标志物
本研究纳入816名≥60岁社区居住老年人,检测血清RBP4并评估肌少症相关指标。结果显示肌少症患者血清RBP4水平更高,且与肌少症风险及严重程度相关,提示RBP4可能作为肌少症筛查与评估的替代生物标志物。
要点
- 肌少症患者血清RBP4水平高于非肌少症者。
- 血清RBP4预测肌少症的最佳截断值为38.79 μg/mL。
- 血清RBP4较高者肌少症风险增加,且与严重程度相关。
核心结论
- 血清RBP4水平与老年人肌少症的风险和严重程度相关,可能作为筛查和评估肌少症的替代生物标志物。
研究设计与样本
- 研究纳入816名≥60岁社区居住老年人,采用酶联免疫吸附法测定血清RBP4,并测量四肢骨骼肌质量指数、握力和步速。
主要发现
- 肌少症患者血清RBP4水平为44.3 [33.9-57.7] μg/mL,高于非肌少症者的38.0 [28.0-48.4] μg/mL。
- 血清RBP4预测肌少症的最佳截断值为38.79 μg/mL,灵敏度67.8%,特异度53.3%。
- 多因素logistic回归显示,血清RBP4较高者肌少症风险更高(调整OR=2.036,95%CI=1.449-2.861)。
- 血清RBP4与握力(r=-.098)、步速(r=-.186)和四肢骨骼肌质量指数(r=-.096)呈负相关。
- 严重肌少症患者血清RBP4水平为49.0 [37.3-61.2] μg/mL,高于中度肌少症患者的40.4 [31.3-51.2] μg/mL。
关键数值与推荐
- 血清RBP4预测肌少症的最佳截断值为38.79 μg/mL,灵敏度67.8%,特异度53.3%。
- 血清RBP4较高者肌少症风险的调整OR=2.036(95%CI=1.449-2.861)。
临床怎么用
- 在老年综合评估中可考虑检测血清RBP4辅助筛查肌少症风险。
- 血清RBP4水平较高时需关注肌少症严重程度并进一步评估肌肉功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sarcopenia is characterized by progressive loss of muscle mass and function due to aging. Retinol-binding protein 4 (RBP4) is an adipokine with pro-inflammatory effects. However, the change of RBP4 concentration and its role in sarcopenia remains unclear. The aim of this study was to evaluate the association of serum RBP4 level with sarcopenia in the older adults. A total of 816 community-dwelling older adults aged ≥60 years were enrolled. Serum RBP4 was measured by enzyme-linked immunosorbent assay. Appendicular skeletal muscle mass index (ASMI), grip strength, and gait speed were measured. We found that serum RBP4 levels were higher in patients with sarcopenia when compared with those without sarcopenias (44.3 [33.9-57.7] vs 38.0 [28.0-48.4] μg/mL). Receiver operating characteristic curve analysis indicated that the optimal cutoff value of serum RBP4 level that predicted sarcopenia was 38.79 μg/mL with a sensitivity of 67.8% and a specificity of 53.3%. Multivariate logistic regression analysis showed that the subjects with a higher level of RBP4 had a higher risk of sarcopenia (adjusted odds ratio [OR] = 2.036, 95% CI = 1.449-2.861). Serum RBP4 concentration was negatively correlated with grip strength (r = -.098), gait speed (r = -.186), and AMSI (r = -.096). Moreover, serum RBP4 levels were higher in patients with severe sarcopenia when compared with those with moderate sarcopenia (49.0 [37.3-61.2] vs 40.4 [31.3-51.2] μg/mL). Taken together, our results demonstrate that serum RBP4 level is correlated with the risk and severity of sarcopenia in the older adults, indicating that RBP4 might serve as a surrogate biomarker for the screening and evaluation of sarcopenia.
引用
- Chang CL, Li YR, Wang ZY, et al. Serum Retinol Binding Protein 4 as a Potential Biomarker for Sarcopenia in Older Adults. J Gerontol A Biol Sci Med Sci. 2023. PMID: 35857418. doi:10.1093/gerona/glac151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。